After revolutionizing treatment of blood cancers, imatinib stands poised to eradicate malaria

Thomas Bradley named director of hematology and oncology at Northwell’s Florina Cancer Center

Thomas Bradley has been appointed director of hematology and oncology at Staten Island University Hospital’s Florina Cancer Center to spearhead the division’s clinical, educational, and research initiatives.

October 25, 2024

Vol.50 No.40

In Brief

Michael Seidman joins Fox Chase Department of Hematology/Oncology

Michael Seidman has joined Fox Chase Cancer Center as a professor in the Department of Hematology/Oncology.

August 09, 2024

Vol.50 No.32

Clinical Trials & Tribulations

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

At its most recent meeting, the FDA Oncologic Drugs Advisory Committee focused on perioperative clinical trials, which the agency defined as neoadjuvant phase followed by surgery and continuing with adjuvant treatment using the same experimental agent (The Cancer Letter, July 26, 2024).

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.

July 26, 2024

Vol.50 No.30

By Jacquelyn Cobb and Paul Goldberg

Clinical Roundup

Cell donor’s socioeconomic status shapes cancer treatment outcomes

The socioeconomic status of cell donors affects the health outcomes of blood cancer patients who underwent hematopoietic cell transplantation, according to a new study led by researchers at the University of Minnesota Medical School.

July 19, 2024

Vol.50 No.29

Conversation with The Cancer Letter

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence

More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.

July 12, 2024

Vol.50 No.28

By Matthew Bin Han Ong

After revolutionizing treatment of blood cancers, imatinib stands poised to eradicate malaria

YOU MAY BE INTERESTED IN

Thomas Bradley named director of hematology and oncology at Northwell’s Florina Cancer Center

Michael Seidman joins Fox Chase Department of Hematology/Oncology

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

Cell donor’s socioeconomic status shapes cancer treatment outcomes

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence

Renew today!

Subscriber content

Login

After revolutionizing treatment of blood cancers, imatinib stands poised to eradicate malaria

YOU MAY BE INTERESTED IN

Thomas Bradley named director of hematology and oncology at Northwell’s Florina Cancer Center

Michael Seidman joins Fox Chase Department of Hematology/Oncology

Of adaptive and factorial designsA biostatistician’s interpretation of last week’s ODAC

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

Cell donor’s socioeconomic status shapes cancer treatment outcomes

Infections are a major cause of death in patients treated with CAR T-cell therapyMeta-analysis focused on causes of death, excluding relapse, recurrence

Login

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence